News & Updates
Filter by Specialty:
![[Infographics] Don’t stop at HF: Screen for ATTR-CM](https://prdmspst.blob.core.windows.net/images/articles/hk-pfi-846md00-89295b22-49b4-4b25-954e-9d780710ea04-square.png)
STEMI criteria show similar accuracy in right BBB, non-BBB patients
The ECG criteria used for identifying patients with ST-elevation myocardial infarction (STEMI) demonstrates similar diagnostic accuracy in right bundle branch block (BBB) and non-BBB patients, according to a study.
STEMI criteria show similar accuracy in right BBB, non-BBB patients
27 Aug 2024
Preterm preeclampsia screen-and-prevent strategy to launch across HK’s public hospitals after initial success
A screen-and-prevent strategy for preterm preeclampsia (PE), which involves screening in the first trimester and low-dose aspirin prophylaxis for high-risk women in <16–36 weeks of gestation, will be launched in obstetric units of public hospitals across Hong Kong following promising results from a multicentre Asian trial led by the Chinese University of Hong Kong (CUHK) and a pilot programme at the Prince of Wales Hospital (PWH).
Preterm preeclampsia screen-and-prevent strategy to launch across HK’s public hospitals after initial success
27 Aug 2024
Management of DKD: Current knowledge and practical insights
Diabetic kidney disease (DKD) is a global healthcare burden. At a symposium co-organized by Diabetes Hongkong and Hong Kong Society of Nephrology, Professor Ronald Ma of the Chinese University of Hong Kong discussed the current landscape of DKD in Hong Kong, and Dr Masayuki Yamanouchi, a specialist in nephrology from Toranomon Hospital in Tokyo, Japan, discussed clinical and real-world evidence on the effects of a nonsteroidal mineralocorticoid receptor antagonist (MRA), finerenone, in improving outcomes in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). Dr Yamanouchi also presented two patient cases to illustrate the clinical benefits of finerenone in DKD patients with different disease severity.
